Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Uterine Artery Blood Flow in Pregnant Women With PCOS Treated With Metformin
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 48
- Registration Number
- NCT00466622
- Locations
- 🇳🇴
Dept. of Obstetrics and Gynecology, National Center for fetal Medicine, University Hospital of Trondheim, Trondheim, Norway
The Effect of Metformin Treatment on Thyroid Hormone Metabolism in Euthyroid Patients With Type 2 Diabetes Mellitus
- Conditions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2007-04-20
- Lead Sponsor
- Haydarpasa Numune State Hospital
- Registration Number
- NCT00463502
A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects
- Conditions
- Interventions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 97
- Registration Number
- NCT00454233
- Locations
- 🇷🇺
4 Sites, Moscow, Russian Federation
🇷🇺10 Sites, St. Petersburg, Russian Federation
Metformin and Oral Contraceptives in PCOS
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT00451568
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain
- Conditions
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- Central South University
- Target Recruit Count
- 128
- Registration Number
- NCT00451399
- Locations
- 🇨🇳
Institute of Mental Health of The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-03-20
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 508
- Registration Number
- NCT00449605
- Locations
- 🇨🇱
Sanofi-aventis adminsitrative office, Santiago, Chile
🇸🇪Sanofi-Aventis Administrative Office, Bromma, Sweden
Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2024-11-19
- Target Recruit Count
- 82
- Registration Number
- NCT00445627
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance
- Conditions
- Interventions
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 28
- Registration Number
- NCT00443755
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Medication in Early Diabetes (MED) Study
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Menzies School of Health Research
- Registration Number
- NCT00437970
- Locations
- 🇦🇺
Menzies School of Health Research, Darwin, Northern Territory, Australia
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 803
- Registration Number
- NCT00432276
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.